WO2002068629A3 - Constructions d'adn pour expression cytoplasmique et mitochondriale et procedes de production et d'utilisation de ces constructions - Google Patents

Constructions d'adn pour expression cytoplasmique et mitochondriale et procedes de production et d'utilisation de ces constructions Download PDF

Info

Publication number
WO2002068629A3
WO2002068629A3 PCT/US2002/000543 US0200543W WO02068629A3 WO 2002068629 A3 WO2002068629 A3 WO 2002068629A3 US 0200543 W US0200543 W US 0200543W WO 02068629 A3 WO02068629 A3 WO 02068629A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
expression
mithochondrial
cytoplasmic
making
Prior art date
Application number
PCT/US2002/000543
Other languages
English (en)
Other versions
WO2002068629A2 (fr
Inventor
Cahterine J Pachuk
Daniel Edward Mccallus
Original Assignee
Wyeth Corp
Satishchandran Chandrasekhar
Cahterine J Pachuk
Daniel Edward Mccallus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Satishchandran Chandrasekhar, Cahterine J Pachuk, Daniel Edward Mccallus filed Critical Wyeth Corp
Priority to AU2002306406A priority Critical patent/AU2002306406A1/en
Publication of WO2002068629A2 publication Critical patent/WO2002068629A2/fr
Publication of WO2002068629A3 publication Critical patent/WO2002068629A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions et des procédés permettant d'acheminer des séquences d'acides nucléiques hétérologues dans les cellules d'une personne. L'utilisation de promoteurs mitochondriaux permet de favoriser l'expression de polypeptides voulus à l'intérieur des cellules de personnes traitées. L'invention concerne également des compositions et des procédés qui peuvent être employés pour traiter et immuniser des personnes contre des pathogènes. L'invention concerne enfin des compositions et des procédés destinés au traitement de personnes par administration de séquences d'acides nucléiques hétérologues voulues au moyen de la thérapie génique.
PCT/US2002/000543 2001-01-09 2002-01-09 Constructions d'adn pour expression cytoplasmique et mitochondriale et procedes de production et d'utilisation de ces constructions WO2002068629A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002306406A AU2002306406A1 (en) 2001-01-09 2002-01-09 Dna constructs for cytoplasmic and mithochondrial expression and methods of making and using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26042701P 2001-01-09 2001-01-09
US60/260,427 2001-01-09

Publications (2)

Publication Number Publication Date
WO2002068629A2 WO2002068629A2 (fr) 2002-09-06
WO2002068629A3 true WO2002068629A3 (fr) 2003-03-13

Family

ID=22989119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000543 WO2002068629A2 (fr) 2001-01-09 2002-01-09 Constructions d'adn pour expression cytoplasmique et mitochondriale et procedes de production et d'utilisation de ces constructions

Country Status (2)

Country Link
AU (1) AU2002306406A1 (fr)
WO (1) WO2002068629A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9410173B2 (en) 2012-10-24 2016-08-09 Clontech Laboratories, Inc. Template switch-based methods for producing a product nucleic acid
EP3760733A1 (fr) 2013-10-17 2021-01-06 Takara Bio USA, Inc. Procédés pour ajouter des adaptateurs à des acides nucléiques et compositions pour leur mise en uvre
WO2015094861A1 (fr) 2013-12-17 2015-06-25 Clontech Laboratories, Inc. Procédés d'ajout d'adaptateurs à des acides nucléiques et compositions pour leur mise en œuvre
EP3091083B1 (fr) * 2015-05-07 2017-11-08 Latvian Biomedical Research and Study Centre Kit de détection d'une mutation ou d'un polymorphisme dans l'adn mitochondrial humain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223247A2 (fr) * 1985-11-22 1987-05-27 Ciba-Geigy Ag Transfert direct de gènes dans des plastides et des mitochondries
WO1998033927A1 (fr) * 1997-01-31 1998-08-06 E.I. Du Pont De Nemours And Company Plantes transformees genetiquement presentant une resistance aux herbicides inhibant la biosynthese des porphyrinogenes
US6218145B1 (en) * 1998-04-02 2001-04-17 Monsanto Company Bacterial expression systems based on plastic or mitochondrial promoter combinations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223247A2 (fr) * 1985-11-22 1987-05-27 Ciba-Geigy Ag Transfert direct de gènes dans des plastides et des mitochondries
WO1998033927A1 (fr) * 1997-01-31 1998-08-06 E.I. Du Pont De Nemours And Company Plantes transformees genetiquement presentant une resistance aux herbicides inhibant la biosynthese des porphyrinogenes
US6218145B1 (en) * 1998-04-02 2001-04-17 Monsanto Company Bacterial expression systems based on plastic or mitochondrial promoter combinations

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ANZIANO P Q ET AL: "Splicing-defective mutants of the yeast mitochondrial COXI gene can be corrected by transformation with a hybrid maturase gene.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 1 JUL 1991, vol. 88, no. 13, 1 July 1991 (1991-07-01), pages 5592 - 5596, XP002221675, ISSN: 0027-8424 *
BINDER S ET AL: "A novel pea mitochondrial in vitro transcription system recognizes homologous and heterologous mRNA and tRNA promoters.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 22 SEP 1995, vol. 270, no. 38, 22 September 1995 (1995-09-22), pages 22182 - 22189, XP002221678, ISSN: 0021-9258 *
BOGENHAGEN D F: "Interaction of mtTFB and mtRNA polymerase at core promoters for transcription of Xenopus laevis mtDNA.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 17 MAY 1996, vol. 271, no. 20, 17 May 1996 (1996-05-17), pages 12036 - 12041, XP002221677, ISSN: 0021-9258 *
CLAYTON D A: "Transcription and replication of mitochondrial DNA.", HUMAN REPRODUCTION (OXFORD, ENGLAND) ENGLAND JUL 2000, vol. 15 Suppl 2, July 2000 (2000-07-01), pages 11 - 17, XP009001234, ISSN: 0268-1161 *
COLLOMBET J M ET AL: "Introduction of plasmid DNA into isolated mitochondria by electroporation. A novel approach toward gene correction for mitochondrial disorders.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 21 FEB 1997, vol. 272, no. 8, 21 February 1997 (1997-02-21), pages 5342 - 5347, XP002221676, ISSN: 0021-9258 *
COLLOMBET J M ET AL: "TOWARDS GENE THERAPY OF MITOCHONDRIAL DISORDERS", MOLECULAR MEDICINE TODAY, ELSEVIER, CAMBRIDGE, GB, vol. 4, no. 1, January 1998 (1998-01-01), pages 31 - 38, XP000946133, ISSN: 1357-4310 *
FARRÉ J C ET AL: "Gene expression in isolated plant mitochondria: high fidelity of transcription, splicing and editing of a transgene product in electroporated organelles.", NUCLEIC ACIDS RESEARCH. ENGLAND 15 JUN 2001, vol. 29, no. 12, 15 June 2001 (2001-06-15), pages 2484 - 2491, XP002221680, ISSN: 1362-4962 *
MCGREGOR A ET AL: "Absence of expression from RNA internalised into electroporated mammalian mitochondria.", MOLECULAR GENETICS AND GENOMICS: MGG. GERMANY JUN 2001, vol. 265, no. 4, June 2001 (2001-06-01), pages 721 - 729, XP002221681, ISSN: 1617-4615 *
SEIBEL PETER ET AL: "Transfection of mitochondria: Strategy towards a gene therapy of mitochondrial DNA diseases", NUCLEIC ACIDS RESEARCH, IRL PRESS LTD., OXFORD, GB, vol. 23, no. 1, 1995, pages 10 - 17, XP002147659, ISSN: 0305-1048 *
SEWARDS R ET AL: "Apparent functional independence of the mitochondrial and nuclear transcription systems in cultured human cells.", MOLECULAR & GENERAL GENETICS: MGG. GERMANY 15 DEC 1994, vol. 245, no. 6, 15 December 1994 (1994-12-15), pages 760 - 768, XP001120079, ISSN: 0026-8925 *
WHEELER V C ET AL: "Modification of the mouse mitochondrial genome by insertion of an exogenous gene", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER SCIENCE PUBLISHERS, BARKING, GB, vol. 198, no. 1-2, 1 October 1997 (1997-10-01), pages 203 - 209, XP004116057, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
AU2002306406A1 (en) 2002-09-12
WO2002068629A2 (fr) 2002-09-06

Similar Documents

Publication Publication Date Title
WO2004033620A3 (fr) Procedes et compositions permettant l'utilisation therapeutique de l'interference arn
DE60038011D1 (de) Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
EP1712243A4 (fr) Therapie genique pour tumeur utilisant un vecteur viral a arn a chaine negative codant une cytokine immunostimulatrice
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
WO2003010284A3 (fr) Modulation antisens de l'expression de la proteine reactive c
WO2003008543A3 (fr) Modulation antisens de l'expression de la proteine x associee a bcl2
WO2003000907A3 (fr) Transfection amelioree de cellules eucaryotes avec polynucleotides lineaires par electroporation
WO2003038112A3 (fr) Composition et methode permettant de modifier la masse maigre et les proprietes osseuses d'un sujet
WO2003022222A3 (fr) Modulation anti-sens de l'expression d'une proteine kinase r
GB0418388D0 (en) Cell therapy
WO2003105755A3 (fr) Modulation antisens de l'expression du facteur de croissance endotheliale vasculaire c (vegf-c)
MXPA05010575A (es) Peptacuerpo para el tratamiento del cancer.
WO2002068629A3 (fr) Constructions d'adn pour expression cytoplasmique et mitochondriale et procedes de production et d'utilisation de ces constructions
WO2003104397A3 (fr) Modulation antisens de l'expression de la proteine kinase gr 6
WO2004084927A3 (fr) Procedes d'induction d'immunotolerance et compositions utilisees dans ces procedes
WO2003050244A3 (fr) Modulation antisens de l'expression de recepteur etbr-lp-2 couple aux proteines g
WO2001081404A3 (fr) VECTEUR PLASMIDIQUE INDUCTIBLE CODANT TGF-ss, ET SES UTILISATIONS
WO1999042137A3 (fr) Regulation de genes therapeutiques par un promoteur de stress en therapie genique, et compositions et procedes associes
WO2005049793A3 (fr) Methodes et compositions destinees a des approches combinatoires pour la therapie genique du cancer
ITMI20030860A1 (it) Metodo per l'inibizione selettiva del gene n-myc
WO2003090778A3 (fr) Vaccin a l'adn combine et modificateurs biologiques utilises dans le traitement du cancer
AU5023096A (en) Nucleotide and deduced amino acid sequences of tumor gene int6
WO2003040161A3 (fr) Modulation antisens de l'expression du facteur de transcription activateur 3
WO2003105754A3 (fr) Modulation antisens de l'expression du facteur de croissance endotheliale vasculaire b (vegf-b)
WO2003016343A3 (fr) UTILISATION DE αCP1, DE αCP2, ET DE HUR POUR MODULER L'EXPRESSION GENIQUE ET ACTIVER L'ANGIOGENESE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP